Pharming Group Overview
- Year Founded
-
1988
- Status
-
Public
- Employees
-
404
- Stock Symbol
-
PHARM
- Investments
-
9
- Share Price
-
$1.02
- (As of Monday Closing)
Pharming Group General Information
Description
Pharming Group is a biopharmaceutical company focused in transforming the lives of patients with rare, debilitating, and life-threatening diseases. The company is actively developing and commercializing a diverse portfolio of innovative treatments, including both biologics and small molecule therapies. Its commercial products are RUCONEST, approved for the treatment of acute attacks in adult and adolescent patients with hereditary angioedema, or HAE; and Joenja (leniolisib), a small-molecule kinase inhibitor, developed for the treatment of activated phosphoinositide 3-kinase delta syndrome.
Contact Information
Website
www.pharming.comCorporate Office
- Vondellaan 47
- 2332 AA Leiden
- Netherlands
Corporate Office
- Vondellaan 47
- 2332 AA Leiden
- Netherlands
Pharming Group Stock Performance
As of 14-Jul-2025, Pharming Group’s stock price is $1.02. Its current market cap is $697M with 684M shares.
(As of Monday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $1.02 | $1.01 | $0.71 - $1.25 | $697M | 684M | 9.9M | -$0.02 |
Pharming Group Financials Summary
As of 31-Mar-2025, Pharming Group has a trailing 12-month revenue of $321M.
|
In Thousands, USD |
TTM 31-Mar-2025 | FY 2024 31-Dec-2024 | FY 2023 31-Dec-2023 | FY 2022 31-Dec-2022 |
|---|---|---|---|---|
| EV | 514,898 | 608,254 | 718,479 | 704,305 |
| Revenue | 320,708 | 297,200 | 245,316 | 205,622 |
| EBITDA | 16,947 | 7,844 | 2,758 | 33,448 |
| Net Income | (14,112) | (11,841) | (10,548) | 13,674 |
| Total Assets | 403,181 | 399,985 | 462,854 | 425,797 |
| Total Debt | 119,143 | 112,313 | 171,545 | 166,694 |
Pharming Group Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Pharming Group Comparisons
Industry
Financing
Details
Pharming Group Competitors (44)
One of Pharming Group’s 44 competitors is uniQure, a Formerly VC-backed company based in Amsterdam, Netherlands.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| uniQure | Formerly VC-backed | Amsterdam, Netherlands | ||||
| Inventiva Pharma | Corporation | Daix, France | ||||
| Adaptimmune Therapeutics | Formerly VC-backed | Abingdon, United Kingdom | ||||
| Renova Therapeutics | Venture Capital-Backed | Carlsbad, CA | ||||
| Achaogen | Formerly VC-backed | South San Francisco, CA |
Pharming Group Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Pharming Group Patents
Pharming Group Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| CA-3225079-A1 | Using c1 esterase inhibitor to treat viral infection-related symptoms | Pending | 09-Jul-2021 | ||
| EP-4366761-A1 | Using c1 esterase inhibitor to treat viral infection-related symptoms | Inactive | 09-Jul-2021 | ||
| US-20240342258-A1 | Using c1 esterase inhibitor to treat viral infection-related symptoms | Pending | 09-Jul-2021 | ||
| ES-2981341-T3 | C1 esterase inhibitor for treating respiratory distress associated with coronavirus infection | Active | 17-Apr-2020 | ||
| EP-4135756-B1 | C1 esterase inhibitor to treat coronaviral infection-related respiratory distress | Active | 17-Apr-2020 | A61K38/57 |
Pharming Group Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Pharming Group Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
Pharming Group Investments & Acquisitions (9)
Pharming Group’s most recent deal was a Merger/Acquisition with Abliva for . The deal was made on 06-Mar-2025.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Abliva | 06-Mar-2025 | Merger/Acquisition | Pharmaceuticals | ||
| Pharming Group (EU Commercial Rights) | 01-Jan-2020 | Corporate Asset Purchase | Buildings and Property | ||
| Novartis (Leniolisib) | 13-Aug-2019 | Corporate Asset Purchase | Buildings and Property | ||
| BioConnection | 09-Apr-2019 | Corporate | BPO/Outsource Services | ||
| BioConnection | 09-Apr-2019 | Secondary Transaction - Private | BPO/Outsource Services |
Pharming Group ESG
Risk Overview
Risk Rating
Updated May, 31, 2024
25.44 | Med Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
Management
Management is related to actions taken to manage ESG issues
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
of 14,697
Rank
Percentile
Pharmaceuticals
Industry
of 847
Rank
Percentile
Biotechnology
Subindustry
of 368
Rank
Percentile
Pharming Group Exits (1)
Pharming Group’s most recent exit was on 23-Mar-2006 from Dnage. The exit was categorized as .
| Company Name | Exit Date | Exit Type | Exit Size | Status | Buyers |
|---|---|---|---|---|---|
| Dnage | 23-Mar-2006 | Completed |
|
Pharming Group Affiliates
Subsidiaries (1)
| Name | Industry | Location | Year Founded |
|---|---|---|---|
| Abliva | Lund, Sweden | 2000 |
Pharming Group FAQs
-
When was Pharming Group founded?
Pharming Group was founded in 1988.
-
Where is Pharming Group headquartered?
Pharming Group is headquartered in Leiden, Netherlands.
-
What is the size of Pharming Group?
Pharming Group has 404 total employees.
-
What industry is Pharming Group in?
Pharming Group’s primary industry is Pharmaceuticals.
-
Is Pharming Group a private or public company?
Pharming Group is a Public company.
-
What is Pharming Group’s stock symbol?
The ticker symbol for Pharming Group is PHARM.
-
What is the current stock price of Pharming Group?
As of 14-Jul-2025 the stock price of Pharming Group is $1.02.
-
What is the current market cap of Pharming Group?
The current market capitalization of Pharming Group is $697M.
-
What is Pharming Group’s current revenue?
The trailing twelve month revenue for Pharming Group is $321M.
-
Who are Pharming Group’s competitors?
uniQure, Inventiva Pharma, Adaptimmune Therapeutics, Renova Therapeutics, and Achaogen are some of the 44 competitors of Pharming Group.
-
What is Pharming Group’s annual earnings per share (EPS)?
Pharming Group’s EPS for 12 months was -$0.02.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read blog » -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process »
